Skip to main content

Christian Tobogan's Library tagged Pharma →  View Popular

13 Oct 09

FT.com / UK - How Roche and Genentech fell out and made up

  • After all, Avastin, the "blockbuster" cancer treatment, was first identified and
    cloned during the "discretionary time" allocated to Napoleone Ferrara, one of
    Genentech's scientists, in 1989.
01 Sep 09

Clinical Psychology and Psychiatry: A Closer Look: Key Opinion Leader Syndrome

(A) A pervasive pattern of travelling to scientific conferences and talking about research data that he has had no involvement in generating.
(B) Episodic logosagnosia.
(C) Unusual abilities to compartmentalise information.
(D) Will have a significant number of ‘‘ghost-written” articles.
(E) Actively seeks admiration by peers and subordinates.
(F) An exaggerated sense of own talents, which can be inferred from expectations of recognition as an expert in the absence of commensurate achievements. Happy in the role of opinion leader.
(G) Has a sense of entitlement, i.e. unreasonable expectations of favorable treatment from symposium and congress organisers.
(H) Liable to profound dysphoria if not involved with the ‘‘academic action”.
(I) May be unreasonably envious of the scientific achievements of others and is liable to denigrate these. Would also be unhappy if his colleagues had appeared on ‘‘educational” videos and he had not.
(J) Is unaware of the disorder quality of the syndrome.

clinpsyc.blogspot.com/...y-opinion-leader-syndrome.html - Preview

pharma

  • (A) A pervasive pattern of travelling to scientific conferences and talking about research data that he has had no involvement in generating.
    (B) Episodic logosagnosia.
    (C) Unusual abilities to compartmentalise information.
    (D) Will have a significant number of ‘‘ghost-written” articles.
    (E) Actively seeks admiration by peers and subordinates.
    (F) An exaggerated sense of own talents, which can be inferred from expectations of recognition as an expert in the absence of commensurate achievements. Happy in the role of opinion leader.
    (G) Has a sense of entitlement, i.e. unreasonable expectations of favorable treatment from symposium and congress organisers.
    (H) Liable to profound dysphoria if not involved with the ‘‘academic action”.
    (I) May be unreasonably envious of the scientific achievements of others and is liable to denigrate these. Would also be unhappy if his colleagues had appeared on ‘‘educational” videos and he had not.
    (J) Is unaware of the disorder quality of the syndrome.
23 Aug 09

Why Pharma Wants ObamaCare - Forbes.com

  • The reason: The drug industry has transformed from a business that tries to sell pills to the masses to one that markets very expensive treatments to small groups of sick people--and that changes everything
  • This generic flood is one reason pharma is protected from the health care reform debate. Drug costs are only a 10th of health care spending anyway, and they're expected to grow at only 2% a year going forward. There's a real possibility sales will shrink.
  • 2 more annotations...
29 Jul 09

Craziness of new psychological disorders - The Boston Globe

  • “The drug barons’ ongoing campaign to pathologize entirely natural emotional responses to hunger, humiliation, financial insecurity, racism, sexism, overwork, and isolation is a mercenary tactic, designed to create markets, maximize profits, and minimize dissidence,’’ Eugenia Tsao writes in the current CounterPunch. You would think the APA would respond to these accusations of self-dealing, but a spokeswoman assured me that DSM representatives were too busy to speak with me.
18 Mar 09

Why big pharma mergers magnify failures - The Atlantic Business Channel

  • the
    marketing-driven demands of the global giants
  • I believe that it is not a failure of science but rather the context in
    which such science is practiced.
  • 5 more annotations...
06 Mar 09

On Vaccines and Autism : Bio Job Blog

  • The furor surrounding childhood vaccines began when Wakefield, a British gastroenterologist, published a Lancet article in 1998 claiming to show a link between the measles-mumps-rubella vaccine (MMR) and development of autism in children
  • The original Wakefield paper has been retracted by 10 of the 13 authors.
  • 2 more annotations...
05 Mar 09

Pharmafocus.com

  • Nick Stephens is chief executive of RSA
  • here's no reason to do it [R&D] here anymore. The margin is too tight, there's now no reason to keep R&D here
  • 6 more annotations...
25 Feb 09

As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients - FierceBiotech

  • The JUPITER trial enrolled apparently healthy subjects without high LDL cholesterol but with elevated hsCRP and randomized subjects to receive Crestor or placebo. Trial data showed a 44 percent reduction in major cardiovascular events and reduced all-cause mortality by 20 percent among participants receiving Crestor.
  • "Our findings suggest that in response to the JUPITER trial data, many clinicians will start using a statin ahead of diet and exercise changes
22 Jan 09

TheDay.com - Even Pfizer Has Fallen Upon Some Hard Times

  • “Initiatives are changed every six months. Performance management is a joke. We can't do the job, because every time we get traction we get told to do something else
  • David Cadden, a professor of business at Quinnipiac University in Hamden, said Pfizer's problems are emblematic of Wall Street executives who believe they must preserve management at all costs while sacrificing the very souls of their business - in this case, the research scientists who create new products for Pfizer to sell.
  • 19 more annotations...

Can Pfizer weather the coming storms? - FiercePharma

  • For instance, as Big Pharma got bigger, companies didn't realize that R&D productivity doesn't scale. "If anything, it may go in the other direction,"
  • "Having finance people and lawyers without scientific knowledge who don't know a neutron from a crouton... making decisions about a viable research project is a problem,
15 Jan 09

The IN VIVO Blog: What’s Wrong with Pharma? One Answer from JP Morgan

      • Some of Big Pharma’s very senior managers (one assumes not excluding the speaker) are very sharp. But there’s a huge fall-off in quality as you get below the top.

      • Big Pharma managers, trained in consensus decision making, don’t take individual responsibility. Not a lot of bold decisions, therefore, likely to get made.

      • Pricing in pharma will change to a pay-for-performance model.

      • This industry – and all its constituents – hates bad news. So rather than confront it, managers generally try to avoid it, exacerbating the problems pharma faces.

      • Given the R&D productivity problems, in-licensing is crucial – but no one wants to say "yes" to them. Everyone will remember the executive who championed an in-licensing candidate that fails after millions in trial expenses. No one remembers the person who said “no” to Lipitor.

      • If that ain't enough to block most deals, the not-invented-here syndrome can help. NIH remains a powerful force in pharma: fundamentally, all R&D heads all want to develop their own drugs.

      • Pharma will evolve to a holding company model – it’s just too complex to run as it is.
  • And finally: “I’d find a great head of R&D. Good marketing guys are common; great R&D heads are very, very rare.”
16 Dec 08

P&G looking to drop drugs | Cincinnati Enquirer | Cincinnati.Com

  • The company entered the pharmaceuticals business in 1982
  • In 1999, investors beat up P&G's stock after the company explored a $140 billion merger that would have made it an instant drug-industry giant. The company in 2000 ended negotiations to buy drug giants Warner-Lambert Co. and American Home Products Corp
23 Oct 08

PharmaTimes | Industry News | World News | Belgium bids for biopharma investments


  • In absolute terms, Belgium in the world’s leading exporter of medicines,
  • that the health sector in Belgium is likely to be severely affected by the country’s current political turmoil, with concerns that the nation may split into separate French- and Flemish-speaking entities.
08 Oct 08

FT.com / Business education - Medicine for a sector

  • It is far too soon to write off the French pharmaceutical sector. But it is having to evolve rapidly in order to survive, with the help of a more international perspective; and more radical, foreign-inspired surgery may yet be required.
1 - 20 of 38 Next ›
Showing 20▼ items per page

Selected Tags

Related Tags

Sponsored Links

Ads by Google

Diigo is about better ways to research, share and collaborate on information. Learn more »

Join Diigo